Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuankai Shi

Showing results (281-290 of 347) with videos related to

Pageof 35
Sort By:
Thoracic Cancer|May 17, 2022
Prevalence and management of pain in lung cancer patients in northern China: A multicenter cross-sectional studyBo Zhang, Xingya Li, Zhiyong Ma, et al.
BMC Cancer|March 18, 2025
Telpegfilgrastim for chemotherapy-induced neutropenia in patients with non-small cell lung cancer: a multicentre, randomized, phase 3 studyYuankai Shi, Xinshuai Wang, Zhidong Pei, et al.
Cancer Pathogenesis and Therapy|February 8, 2024
Clinical characteristics and treatment outcomes of Chinese diffuse large B-cell lymphoma patients in the era of rituximab (2005-2018)Yuankai Shi, Haizhu Chen, Yan Qin, et al.
Haematologica|August 19, 2021
Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA studyLale Kostakoglu, Federico Mattiello, Maurizio Martelli, et al.
The Lancet. Respiratory Medicine|March 29, 2021
Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label studyYuankai Shi, Xingsheng Hu, Shucai Zhang, et al.
Cancer Biology & Medicine|February 16, 2019
Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatmentJing Wang, Yizhuo Zhao, Qiming Wang, et al.
Ebiomedicine|April 19, 2020
Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimabYuankai Shi, Hang Su, Yongping Song, et al.
Blood Advances|March 2, 2021
End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYALale Kostakoglu, Maurizio Martelli, Laurie H Sehn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 20, 2019
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical TrialYi-Long Wu, Shun Lu, Ying Cheng, et al.
Plos One|November 25, 2015
The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective StudyXingsheng Hu, Li Zhang, Yuankai Shi, et al.
Pageof 35

Showing results (281-290 of 347) with videos related to

Sort By:
Pageof 35
Thoracic Cancer|May 17, 2022
Prevalence and management of pain in lung cancer patients in northern China: A multicenter cross-sectional studyBo Zhang, Xingya Li, Zhiyong Ma, et al.
BMC Cancer|March 18, 2025
Telpegfilgrastim for chemotherapy-induced neutropenia in patients with non-small cell lung cancer: a multicentre, randomized, phase 3 studyYuankai Shi, Xinshuai Wang, Zhidong Pei, et al.
Cancer Pathogenesis and Therapy|February 8, 2024
Clinical characteristics and treatment outcomes of Chinese diffuse large B-cell lymphoma patients in the era of rituximab (2005-2018)Yuankai Shi, Haizhu Chen, Yan Qin, et al.
Haematologica|August 19, 2021
Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA studyLale Kostakoglu, Federico Mattiello, Maurizio Martelli, et al.
The Lancet. Respiratory Medicine|March 29, 2021
Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label studyYuankai Shi, Xingsheng Hu, Shucai Zhang, et al.
Cancer Biology & Medicine|February 16, 2019
Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatmentJing Wang, Yizhuo Zhao, Qiming Wang, et al.
Ebiomedicine|April 19, 2020
Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimabYuankai Shi, Hang Su, Yongping Song, et al.
Blood Advances|March 2, 2021
End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYALale Kostakoglu, Maurizio Martelli, Laurie H Sehn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 20, 2019
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical TrialYi-Long Wu, Shun Lu, Ying Cheng, et al.
Plos One|November 25, 2015
The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective StudyXingsheng Hu, Li Zhang, Yuankai Shi, et al.
Pageof 35